EXCHANGE: Siponimod for Relapsing Multiple Sclerosis (RMS)
Protocol: STUDY00003455
Full Title
Exploring the safety and tolerability of conversion to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study (EXCHANGE)
Description
This study enrolls people with advancing Relapsing Multiple Sclerosis (RMS). The purpose of the study is to see how safe and how well tolerated changing from one MS medication to siponimod (an investigational drug for MS) will be.

You will be in this study for about 8 months. During that time you'll come to clinic 6 times for study visits. You will receive a study medication for about 6 months. You will have physical exams, eye exams and cardiac evaluations and you will have blood taken during the study. Study takes place at UBMD outpatient neurology clinic.

Compensation is not available.

Technical Description

The primary objective is to evaluate overall safety and tolerability profile of siponimod in advancing RMS patients (including a broader population that had not been previously studied with siponimod who are converting from currently approved oral or injectable RMS DMT).
Compensation: No
Eligibility
Adults ages 18+.
Diagnosed with Relapsing Multiple Sclerosis (RMS).
Age Group: Adults
ClinicalTrials.gov: Open Study
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.
Thank you for your interest. This study has restricted recruiting for participants and is not accepting inquiries at this time. If you are interested in learning more about research at UB contact ctsiresearch@buffalo.edu.